Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2018, Article ID 4273231, 3 pages
https://doi.org/10.1155/2018/4273231
Case Report

Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome

1University of Illinois College of Medicine at Peoria, Peoria, IL, USA
2Illinois Cancer Care, Peoria, IL, USA

Correspondence should be addressed to Benjamin Chaucer; ude.ciu.pmociu@recuahcb

Received 1 October 2017; Revised 7 December 2017; Accepted 28 December 2017; Published 17 January 2018

Academic Editor: Peter F. Lenehan

Copyright © 2018 Benjamin Chaucer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. OPDIVO, Package Insert, Bristol-Myers Squibb Company, Princeton, NJ, USA, 2016.
  2. HLRCC, Genetics Home Reference, 2017, https://ghr.nlm.nih.gov/condition/hereditary-leiomyomatosis-and-renal-cell-cancer#statistics.
  3. M. Muller, S. Ferlicot, M. Guillaud-Bataille et al., “Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers,” Clinical Genetics, vol. 92, no. 6, pp. 606–615, 2017. View at Publisher · View at Google Scholar
  4. P. Pollard, N. Wortham, E. Barclay et al., “Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome,” Journal of Pathology, vol. 205, no. 1, pp. 41–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Motzer, B. Escudier, D. F. McDermott et al., “Nivolumab versus everolimus in advanced renal cancer carcinoma,” New England Journal of Medicine, vol. 373, no. 19, pp. 1803–1813, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Zimmer, S. M. Goldinger, L. Hofmann et al., “Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD1 therapy,” European Journal of Cancer, vol. 60, pp. 210–225, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Spain, G. Walls, M. Julve et al., “Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature,” Annals of Oncology, vol. 28, no. 2, pp. 377–385, 2016. View at Publisher · View at Google Scholar